Please assess the completion status of the following clinical trial:

Trial Title: GnRHA Therapy and Ovarian Preservation in Pediatric Cancer Patient

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Receiving chemoradiation therapy~* Documented ovarian function~* Require menstrual suppression with GnRHa during chemoradiation therapy~* Patients at the University of Kentucky, Norton Healthcare or Cincinnati Children's Hospital Medical Center~Exclusion Criteria:~* Under 8 years of age and older than 19 years of age~* Male~* Unable to provide consent or assent

- Gender: FEMALE
- Minimum Age: 8 Years
- Maximum Age: 19 Years
- Healthy Volunteers: f

Study Arms:
- Cases (Type: OTHER): Participants who will receive gonadotoxic chemoradiation therapies to include the alkylating agents, heavy metals and plant alkaloids as a standard part of their cancer treatment. Participants will also receive the GnRHa for menstrual suppression as part of standard of care. Baseline blood draws and pelvic ultrasound will be the intervention. Repeat blood draws and pelvic ultrasound at 6 and 12 months will also be interventions.
- Controls (Type: OTHER): Participants who will receive chemoradiation therapies presumed to be low risk for gonadotoxicity as determined by the literature and the patient's oncolologist as a standard part of their cancer treatment. Participants will also receive the GnRHa for menstrual suppression as part of standard of care. Baseline blood draws and pelvic ultrasound will be the intervention. Repeat blood draws and pelvic ultrasound at 6 and 12 months will also be interventions.

Based on this trial design, predict the completion outcome and termination type (if applicable).